Verona Pharmaceuticals, a UK-based clinical-stage biopharmaceuticals company said that it has completed the enrollment of more than 800 subjects randomised in the ENHANCE-2 trial, evaluating ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The company also revealed that top-line data from the two double-blind, placebo-controlled studies are expected in the third quarter of 2022. The company added that ensifentrine is a first-in-class drug candidate that combines bronchodilator and anti-inflammatory activities in one compound, which has shown significant and clinically meaningful improvements in lung function, symptoms and quality of life as a monotherapy or added onto a maintenance bronchodilator.